Documents

Delaby, C.[a b] , Bousiges, O.[c] , Bouvier, D.[d] , Fillée, C.[e] , Fourier, A.[f] , Mondésert, É.[a] , Nezry, N.[g] , Omar, S.[h] , Quadrio, I.[f] , Rucheton, B.[i] , Schraen-Maschke, S.[g] , van Pesch, V.[j] , Vicca, S.[k] , Lehmann, S.[a] , Bedel, A.[l]

Neurofilaments: a key new biomarker for clinicians Part 1: Importance of neurofilaments in the management of neurodegenerative diseases [Les neurofilaments : un nouveau biomarqueur clé pour les cliniciens Partie 1 : Intérêt des neurofilaments dans la prise en charge des maladies neurodégénératives]

(2022) *Annales de Biologie Clinique*, 80 (5), pp. 431-440.

DOI: 10.1684/abc.2022.1757

[a] IRMB, INM, Université de Montpellier, Inserm, CHU de Montpellier, laboratoire de biochimie-protéomique Clinique, Montpellier, France
[b] Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
[c] Laboratoire de biochimie et biologie moléculaire (LBBM), pôle de biologie, Hôpital de Hautepierre, CHU de Strasbourg, laboratoire ICube, CNRS UMR 7357 et Fédération de médecine translationnelle de Strasbourg, équipe IMIS, Strasbourg, France
[d] CHU de Clermont-Ferrand, service de biochimie et génétique moléculaire, Clermont-Ferrand, France
[e] Cliniques universitaires Saint-Luc UCLouvain, service de biochimie médicale, Bruxelles, Belgium
[f] Biochimie et biologie moléculaire - LBMMS, Unité de diagnostic des pathologies dégénératives, Centre de biologie et pathologie Est, Groupement hospitalier Est, Lyon, France
[g] Université de Lille, CHU Lille, Inserm UMR-S-U1172, LiCEND, Lille Neuroscience et Cognition, LabEx DISTALZ, Lille, 59000, France
[h] Laboratoire de biologie médicale de l'Institut de neurologie de Tunis, Tunisia
[i] Laboratoire de biologie, Institut Bergonié, Bordeaux, France
[j] Cliniques universitaires Saint-Luc UCLouvain, service de neurologie, Belgium
[k] Hôpital Necker-Enfants malades, laboratoire de biochimie générale, DMU BioPhyGen, AP-HP, Centre-Université de Paris, France
[l] Service de biochimie, CHU Pellegrin, Université de Bordeaux, place Amélie Raba-Léon, Bordeaux, 33000, France

Abstract
Neurological biomarkers are of great use for clinicians, as they can be used for numerous purposes: guiding clinical diagnosis, estimating prognosis, assessing disease stage and monitoring progression or response to treatment. This field of neurology has evolved considerably in recent years due to analytical improvements in assay methods, now allowing the detection of biomarkers not only in cerebrospinal fluid (CSF) but also in blood. This progress greatly facilitates the repeated quantification of biomarkers, the collection of blood being much less invasive than that of CSF. Among the various informative biomarkers of neurological disorders, neurofilaments light chains (NfL) have proven to be particularly attractive in many contexts, in particular for the diagnosis and prognosis of neurodegenerative diseases (which this review will present), but also in other contexts of neurological disorders (which will be detailed in part 2). We further address the added value of NfL compared to other biomarkers commonly used to monitor the diseases described in this review. © 2022 John Libbey Eurotext. All rights reserved.

Author Keywords
cut-off; diagnosis; neurodegenerative disease; neurofilaments; prognosis

Index Keywords
biological marker; degenerative disease, human, intermediate filament; Biomarkers, Humans, Intermediate Filaments, Neurodegenerative Diseases

Correspondence Address
Lehmann S.; IRMB, France; email: sylvain.lehmann@umontpellier.fr

Publisher: John Libbey

ISSN: 00033898
CODEN: ABCLA
PubMed ID: 36453742
Language of Original Document: French
Abbreviated Source Title: Ann. Biol. Clin.
2-s2.0-85143109991
Document Type: Article
Publication Stage: Final
Source: Scopus